Press Releases May 26, 2026 04:05 PM

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics to present at Jefferies and Goldman Sachs Global Healthcare Conferences in June 2026

By Hana Yamamoto GPCR

Structure Therapeutics announced participation in two major healthcare investor conferences in June 2026 to discuss its development of novel oral small molecule therapeutics targeting metabolic diseases such as obesity. Management will deliver presentations and conduct meetings, with webcasts accessible online.

Structure Therapeutics Announces Participation in Upcoming Investor Conferences
GPCR

Key Points

  • Management will participate in Jefferies and Goldman Sachs Global Healthcare Conferences in early June 2026.
  • The company focuses on developing innovative oral small molecule treatments for metabolic diseases, particularly obesity.
  • Structure Therapeutics leverages a structure-based drug discovery platform targeting GPCRs to develop scalable therapies potentially more accessible than biologics or peptides.

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:

2026 Jefferies Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, June 3 at 12:15 p.m. ET Location:New York, NY   Goldman Sachs 47th Annual Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Tuesday, June 9 at 10:00 a.m. ET Location:Miami, FL


The live and archived webcasts will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for 90 days.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]

Jun Yoon
Structure Therapeutics Inc.
[email protected]

Media:
Dan Budwick
1AB
[email protected]


Risks

  • Clinical-stage drug development carries inherent risks including regulatory approvals and demonstrating efficacy and safety.
  • Market acceptance and competitiveness of oral small molecule therapies in the metabolic disease sector remain uncertain.
  • Dependence on upcoming catalysts such as investor presentations to maintain or improve market interest poses investor relations risks.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Telesat announces results of 2026 Annual General Meeting of shareholders Jun 4, 2026 TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology Jun 4, 2026 Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026